Summary:
2.6% may seem low, but it has been calcu lated that at least 16,000 new cases of infec tion are occurring each year in the United Kingdom. 3 High prevalence of seropositivity is found in adults at special risk, for example 15% of dog breeders in the U. K. 4 Acuity was hand movements. There was a subreti nal inflammatory lesion in the upper temporal quadrant, with vitreoretinal traction producing a band running to the optic disc (Fig. 1 ). There was a dense cellular infiltration of the vitreous.
Anti-toxocara antibodies were found in serum and at higher levels in ocular fluid. Toxocara anti gen was demonstrated in the vitreous and aqueous by a 2-site capture ELISA using a Toxocara canisspecific monoclonal antibody9.
He was treated with thiabendazole (50 mg/Kg/ day) and oral prednisolone for 7 days. Vitrectomy dates could be seen (Fig. 2) .
High levels of anti-toxocara antibodies were found in the serum; toxocara antigen was also found in the serum. There was also an eosinophilia.
Thiabendazole was added to the treatment for 7
days. The acuity improved to 6/12. All signs of inflammation settled, but structural changes remain at the macula. 
Conclusion
We currently propose the following plan of management:
(1) Eye disease alone:
local and periocular or systemic steroids surgery where appropriate (2) Eye disease alone, which does not respond to (l):
add specific anti helminthic and con tinue systemic steroids:
thiabendazole 50 mg/Kg/day for 7 days + prednisolone 0.5-1 mg/Kg/day (3) Eye disease with VLM, or high antibody levels:
local steroids and mydriatics + thiabendazole and systemic steroids as in (2) from the outset.
